Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Boe Technology Group Co., Ltd.

Huawei Technologies Co., Limited

Beijing Boe Optoelectronics Technology Co., Ltd.

Tencent Technology (shenzhen) Company Limited

Chongqing Boe Smart Electronics System Co., Ltd.

Beijing Shenogen Pharma Group Ltd.

Centaurus Biophrama Co., Ltd.

Yuliang Li

Zte Corporation

Yong Peng

Yongxin Han

Hong Luo

Yuandong Hu

Dengming Xiao

Hui Zhang

Li Zhu

Na Zhao

Shanchun Wang

Yinghui Sun

Fansheng Kong

Ling Yang

Hongjiang Xu

Yan Zhu

Xijie Liu

Liguang Dai

Huting Wang

Xiaowei Duan

Xin Tian

Yanqing Yang

Shulong Wang

Bo Liu

Zhe Wang

Xiquan Zhang

Rui Zhao

Hanqing Liu

Zhao Yang

Xinhe Xu

Rong Yu

Jijun Li

Yujie Wu

Zanping Wang

Wenjun Lu

Lei Zhang

Xin Li

Lei Liu

Wei Hu

Bin Zhao

Wei Wu

Gang Yu

Zhihua Liu

Yu Shen

Pengju Zhang

Ling Li

Yonggang Wang

Le Zhang

He Wang

Qiong Wu

Lichun Chen

Kun Meng

Aiming Zhang

Xuchen Yuan

Zhi Liang

Qiangeng Cheng

Honghao Yu

Hongjie Liu

Ying Sun

Jing You

Yangheng Li

Weixiong Chen

Junwei Zhang

Meng Guo

Huiying Li

Xiaoqin Xie

Yongjian Li

Yao Tong

Yuanyuan Huang

Mantang Ma

Quan Hu

Yanbing Zhang

Shengbo Zhang

Ruiyu Zhao

Xianxing Shang

Xiaofeng Zhai

Jian Sun

Yanqing Cai

Zhuomeng Li

Jinqiu Li

Yangfeng Ou

Yongheng Wei

Shousong Cao

Zunwei Ke

Jing Wang

Jiaojiao Wang

Mingji Jin

Lixin Fan

Dongliang Mo

Guang Shen

Dong Wei

Mei Liu

Zhaobai Zhong

Kuncheng Chen

Haining Mo

A content translation method includes displaying, by a terminal, a first user interface, where the first user interface includes a first translation result, and the first translation result is a translation result of first content, detecting, by the terminal, a first operation on the first user interface, displaying, by the terminal, a second user interface in response to the first operation on the first user interface, where the second user interface includes a second translation result, and the second translation result is a translation result of second content, and sending, by the terminal in response to the first operation on the first user interface, third content to a first server to translate the third content, where the second content is associated with the first content, and the third content is associated with the second content.

Content translation method and terminal

A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase allosteric inhibitor or a pharmaceutically acceptable salt thereof in the preparation of drugs for the treatment of tumor diseases.

SHP2 phosphatase allosteric inhibitor

A machine translation method includes: an electronic device displays a first user interface, where source text content is displayed in the first user interface; after detecting an operation of triggering scrolling screenshot taking by a user, the electronic device automatically starts to take a scrolling screenshot; the electronic device obtains a first picture through scrolling screenshot taking; the electronic device obtains translation content corresponding to the source text content displayed on the first picture; and the electronic device automatically displays a second user interface, where a part or all of the translation content is displayed in the second user interface.

Machine translation method and electronic device

A file system permission setting method and apparatus, where an access control list (ACL) permission for a parent node is set such that all child nodes of the parent node inherit the ACL permission for the parent node when a semantic type identifier of an access permission for the parent node is a permission root type.

File system permission setting method and apparatus

An array substrate, a display panel and a display device are provided. The array substrate includes a plurality of gate lines and a plurality of data lines. The plurality of gate lines and the plurality of data lines define rows of sub-pixel regions, each of the sub-pixel regions includes two thin film transistors and a pixel electrode, and the two thin film transistors are both connected with the pixel electrode. Gate electrodes of two thin film transistors in an (n)th row of sub-pixel regions of the rows of sub-pixel regions are respectively connected with an (n)th gate line and an (N+1)th gate line of the plurality of gate lines, K&#x2265;n&#x2265;1, n and K are integers, and K is an amount of rows of the sub-pixel regions.

Array substrate, display panel and display device

Provided is a method for driving an electronic paper display apparatus, including: applying a first driving signal to a first electrode of a microcapsule to be displayed in white, and applying a second driving signal to a first electrode of a microcapsule to be displayed in black according to a black-and-white particle image to be displayed. The first driving signal includes a first sub-driving signal applied in a display stage, wherein the first sub-driving signal is configured to drive the white particles in the microcapsule to be displayed in white to be closer to a display side relative to the black particles. The second driving signal includes a second sub-driving signal applied in the display stage, wherein the second sub-driving signal is configured to drive the black particles in the microcapsule to be displayed in black to be closer to the display side relative to the white particles.

Electronic paper display apparatus and driving method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

A method for manufacturing an array substrate includes: forming a strip-shaped barrier wall(s) on a base substrate, wherein the width of each barrier wall is less than or equal to a distance between a first metal trace to be formed and a second metal trace to be formed; and forming a first metal trace at one side of each barrier wall located in a direction perpendicular to an extending direction of the barrier wall, and forming a second metal trace at an opposite side of the barrier wall located in the direction perpendicular to the extending direction of the barrier wall.

Array substrate and method for manufacturing the same, display device

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers. 

1,3,5-triazine derivative and method of using same

Embodiments of the present disclosure disclose a display substrate, a display panel, a display apparatus, and a method for driving a display apparatus. The display substrate includes: a plurality of first wiring groups each comprising a plurality of first wirings extending in a first direction; a plurality of second wiring groups each comprising a plurality of second wirings and at least one transmission signal line extending in a second direction crossing the first direction; a plurality of first switching circuits each connecting a plurality of first wirings in a corresponding one of the first wiring groups to a control signal line; and a plurality of second switching circuits each connecting a plurality of second wirings in a corresponding one of the second wiring groups to the control signal line.

Display substrate, display panel, display apparatus and method for driving the same

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. 

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase. 

Pyrrolopyrimidine compound

The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases. 

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity

Growing community of inventors

Beijing, China

Yong Peng